Summary
There is very suggestive evidence for a role of serotonin release from platelets in the mechanisms for platelet aggregation, arterial thrombosis, and arterial spasm. These effects are mediated via the 5HT2 receptor and are specifically antagonized by ketanserin. The recently published PACK study was a randomized controlled trial of the effects of ketanserin in patients with intermittent claudication. The purpose of the trial was to discover whether ketanserin treatment would reduce the incidence of atherosclerotic complications such as myocardial infarction or stroke. An unexpected adverse interaction between ketanserin and potassium-losing diuretics was observed, causing an excess of deaths in the group taking this combination of drugs. The “intention-to-treat” analysis showed no overall difference between ketanserin and placebo in terms of cardiovascular complications. Withdrawal of patients taking potassium-losing diuretics left insufficient numbers of patients in the study to answer the original question. However, the “on-treatment” analysis excluding those taking the combination suggested strongly, although did not prove, that ketanserin reduced thrombotic episodes by about 25%. It is concluded that the risks of interactions between many drugs and potassium-losing diuretics make the use of the latter undesirable. Further studies on ketanserin, possibly combined with thromboxane A2 inhibitors, seem highly desirable.
Similar content being viewed by others
References
Doyle AE. Does hypertension predispose to coronary disease? Conflicting epidemiological and experimental evidence. Am J Hypertens 1988;1:319–324.
Moncada S, Vane JR. Arachidonic acid metabolites and interaction between platelets and blood vessel walls. N Engl J Med 1978;300:1142–1147.
Samuelsson B, Goldyne M, Granstrom M, Hammarstrom S, Malansten C. Prostanglandins and thromboxanes. Annu Rev Biochem 1978;47:997–1029.
Rand MJ, Reid G. Source of serotonin in serum. Nature(London) 1951;168:385–386.
Ross R, Vogel A. The platelet derived growth factor. Cell 1978;14:203–210.
De Clerk F, Van Neuten JM. Platelet-mediated vascular contractions: Inhibition of the serotonergic component by ketanserin. Thromb Res 1982;27:713–727.
Moulds RFW, Iwanov Y, Medcalf RL. The effects of platelet-derived contractile agents on human digital arteries. Clin Sci 1984;66:443–451.
Vanhoutte P, Amery A, Birkenhager W, et al. Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin. Hypertension 1988;11:111–133.
Heistad DD, Armstrong ML, Marcus ML, et al. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 1984;54:711–718.
Bogar L, Matrai A, Kennis L, et al. Haemorheological effects of a 5-HT2 receptor antagonist (ketanserin). Clin Haemorheol 1985;5:115–121.
Thulesius O, Lundvall J, Kroese A, et al. Ketanserin in intermittent claudication: Effect on walking distance, blood pressure, and cardiovascular complications. J Cardiovasc Pharmacol 1987;10(Suppl 3)9:S89-S95.
Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989;298:424–430.
McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsades de pointes. Br Heart J 1984;51:157–162.
Klein W, Brandt D, Eber B. Ketanserin for prevention of early restenosis after PTCA. Cardiovasc Drugs Ther 1987;1:257.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction—ISIS-2. Lancet 1988;2:349–360.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Doyle, A.E. Serotonin antagonists and vascular protection. Cardiovasc Drug Ther 4, 13–18 (1990). https://doi.org/10.1007/BF00053421
Issue Date:
DOI: https://doi.org/10.1007/BF00053421